Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)~* Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 cycles of chemotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1~Exclusion Criteria:~* Small cell lung cancer (SCLC) or mixed SCLC and NSCLC~* Central nervous system (CNS) metastases~* Malignancy other than NSCLC~* Palliative radiotherapy for bone lesions inside the thorax~* Prior radiotherapy of bone marrow~* Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)~* Life expectancy \< 6 months~* Woman of child-bearing potential who is pregnant or is breast feeding or who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment~* Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment~* Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products~* Other inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ABP 215 (Type: EXPERIMENTAL): Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
- Bevacizumab (Type: ACTIVE_COMPARATOR): Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).